دورية أكاديمية
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
| العنوان: | Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma |
|---|---|
| المؤلفون: | Tarhini, Ahmad, McDermott, David, Ambavane, Apoorva, Gupte-Singh, Komal, Aponte-Ribero, Valerie, Ritchings, Corey, Benedict, Agnes, Rao, Sumati, Regan, Meredith M, Atkins, Michael |
| المصدر: | Immunotherapy ; volume 11, issue 4, page 283-295 ; ISSN 1750-743X 1750-7448 |
| بيانات النشر: | Informa UK Limited |
| سنة النشر: | 2019 |
| الوصف: | Aim: The cost–effectiveness of treatment sequences in BRAF-mutant advanced melanoma. Materials & methods: A discrete event simulation model was developed to estimate total costs and health outcomes over a patient's lifetime (30 years). Efficacy was based on the CheckMate 067/069 trials and a matching-adjusted-indirect comparison between immuno-oncology and targeted therapies. Safety, cost (in US dollars; US third-party payer perspective) and health-related quality-of-life inputs were based on published literature. Results: Estimated survival gain was higher for sequences initiating with anti-PD-1 + anti-CTLA-4 than for anti-PD-1 monotherapy or BRAF+MEK inhibitors. The incremental cost–effectiveness ratio per QALY gained for first-line anti-PD-1 + anti-CTLA-4 was US$54,273 versus first-line anti-PD-1 and $79,124 versus first-line BRAF+MEK inhibitors. Conclusion: Initiating treatment with anti-PD-1 + anti-CTLA-4 was more cost–effective than initiation with anti-PD-1 monotherapy or BRAF+MEK inhibitors. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.2217/imt-2018-0168 |
| الإتاحة: | https://doi.org/10.2217/imt-2018-0168Test |
| رقم الانضمام: | edsbas.26A0FBD6 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.26A0FBD6 904 3 Academic Journal academicJournal 903.687927246094 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.26A0FBD6&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doi.org/10.2217/imt-2018-0168# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Tarhini%2C+Ahmad%22">Tarhini, Ahmad</searchLink><br /><searchLink fieldCode="AR" term="%22McDermott%2C+David%22">McDermott, David</searchLink><br /><searchLink fieldCode="AR" term="%22Ambavane%2C+Apoorva%22">Ambavane, Apoorva</searchLink><br /><searchLink fieldCode="AR" term="%22Gupte-Singh%2C+Komal%22">Gupte-Singh, Komal</searchLink><br /><searchLink fieldCode="AR" term="%22Aponte-Ribero%2C+Valerie%22">Aponte-Ribero, Valerie</searchLink><br /><searchLink fieldCode="AR" term="%22Ritchings%2C+Corey%22">Ritchings, Corey</searchLink><br /><searchLink fieldCode="AR" term="%22Benedict%2C+Agnes%22">Benedict, Agnes</searchLink><br /><searchLink fieldCode="AR" term="%22Rao%2C+Sumati%22">Rao, Sumati</searchLink><br /><searchLink fieldCode="AR" term="%22Regan%2C+Meredith+M%22">Regan, Meredith M</searchLink><br /><searchLink fieldCode="AR" term="%22Atkins%2C+Michael%22">Atkins, Michael</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Immunotherapy ; volume 11, issue 4, page 283-295 ; ISSN 1750-743X 1750-7448 ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Informa UK Limited ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Aim: The cost–effectiveness of treatment sequences in BRAF-mutant advanced melanoma. Materials & methods: A discrete event simulation model was developed to estimate total costs and health outcomes over a patient's lifetime (30 years). Efficacy was based on the CheckMate 067/069 trials and a matching-adjusted-indirect comparison between immuno-oncology and targeted therapies. Safety, cost (in US dollars; US third-party payer perspective) and health-related quality-of-life inputs were based on published literature. Results: Estimated survival gain was higher for sequences initiating with anti-PD-1 + anti-CTLA-4 than for anti-PD-1 monotherapy or BRAF+MEK inhibitors. The incremental cost–effectiveness ratio per QALY gained for first-line anti-PD-1 + anti-CTLA-4 was US$54,273 versus first-line anti-PD-1 and $79,124 versus first-line BRAF+MEK inhibitors. Conclusion: Initiating treatment with anti-PD-1 + anti-CTLA-4 was more cost–effective than initiation with anti-PD-1 monotherapy or BRAF+MEK inhibitors. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.2217/imt-2018-0168 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://doi.org/10.2217/imt-2018-0168 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.26A0FBD6 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.2217/imt-2018-0168
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tarhini, Ahmad
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => McDermott, David
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ambavane, Apoorva
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gupte-Singh, Komal
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aponte-Ribero, Valerie
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ritchings, Corey
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Benedict, Agnes
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Rao, Sumati
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Regan, Meredith M
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Atkins, Michael
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Immunotherapy ; volume 11, issue 4, page 283-295 ; ISSN 1750-743X 1750-7448
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |